STOCK TITAN
  1. Home
  2. News
  3. SNCE

Science 37 Holdings, Inc. - SNCE STOCK NEWS

Welcome to our dedicated page for Science 37 Holdings news (Ticker: SNCE), a resource for investors and traders seeking the latest updates and insights on Science 37 Holdings stock.

Science 37 Holdings, Inc. (Nasdaq: SNCE) is a pioneering company based in Los Angeles that specializes in accelerating biomedical discovery through innovative, patient-centric clinical research models. Utilizing cutting-edge telemedicine technology, Science 37 offers a comprehensive range of services for conducting networked clinical trials, making it an invaluable partner for investigators, inventors, biotech firms, and large pharmaceutical companies.

At the core of Science 37's operations is the Metasite™, a proprietary virtual site platform that allows patients to participate in clinical trials from the comfort of their own homes or local healthcare providers. Powered by in-house medical and operational experts, the Metasite™ ensures uniform study orchestration, greater compliance, and high-quality data, thereby making clinical trials more accessible and efficient.

Science 37 leverages a vast network of partnerships with national mobile nursing companies, pharmacy chains, patient advocacy groups, and technology companies to streamline the clinical trial process. The company's recent achievements include the successful completion of a reverse stock split and a partnership with leading telemedicine companies, which has significantly expanded its reach and capabilities.

Noteworthy recent developments include the approval of a reverse stock split to comply with Nasdaq listing requirements and the commencement of a cash tender offer by eMed to purchase all outstanding shares of Science 37 at $5.75 per share. This move, coupled with the company's continuous efforts in enhancing patient recruitment through AI-powered screening and centralized processes, underscores its commitment to innovation and operational excellence.

Science 37 has also been recognized for its transformative impact on clinical research, winning the “Clinical Efficiency Innovation Award” at the 8th annual MedTech Breakthrough Awards. This award highlights the company's unique approach to patient recruitment, which has significantly improved patient randomization rates and site satisfaction.

For more detailed information and to stay updated on the latest developments, please visit Science 37's website.

News

Science 37 Provides Fully Consented Patients to Sites to Supplement Enrollment

Rhea-AI Summary
Science 37 Holdings, Inc. launches a Patient Recruitment Solution to provide fully consented patients to sites, leveraging its Metasite™ technology. The new solution aims to accelerate enrollment, reduce site burden, and improve efficiency in patient recruitment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

eMed completes tender offer for all outstanding shares of Science 37

Rhea-AI Summary
eMed, LLC successfully completed the tender offer for Science 37 Holdings, Inc. shares at $5.75 per share, acquiring approximately 77.8% of outstanding shares. The acquisition will be finalized through a merger, with each share converted to $5.75 in cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

eMed commences tender offer for Science 37

Rhea-AI Summary
eMed, LLC initiates a cash tender offer to acquire Science 37 Holdings, Inc. at $5.75 per share, following a Merger Agreement. The Offer expires on March 11, 2024, with no financing condition. Saratoga Proxy Consulting LLC and Continental Stock Transfer & Trust Company are involved in the transaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
none
News

Science 37 to be Acquired by eMed, Expanding Access to Patients and Accelerating Enrollment

Rhea-AI Summary
Science 37 Holdings, Inc. has entered into a definitive merger agreement with eMed, LLC, valued at an equity value of approximately $38 million. The transaction, structured as an all-cash tender offer, will see Science 37 stockholders receiving $5.75 per share. The acquisition is expected to enhance Science 37's ability to access unique patients and enroll studies faster, bringing significant resources for long-term sustainability. The transaction is subject to the tender of a majority of Science 37's outstanding shares of common stock and other customary closing conditions. Upon completion, Science 37 will become a privately held company and shares of Science 37 common stock will no longer be listed on any public market. Additionally, Science 37 provided a business update, with gross bookings of $22.3 million and $102.0 million for the quarter and full year ended December 31, 2023, respectively. Revenue for the full year is expected to be within the most recently issued guidance of $58 to $59 million, and Adjusted EBITDA for the full year is expected to be better than the most recently issued guidance of ($32.5) million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.62%
Tags
acquisition
-
News

Science 37 Receives Top Honors in Everest PEAK Matrix®

Rhea-AI Summary
Science 37 Holdings, Inc. (SNCE) has been recognized as a Leader in the Decentralized Clinical Trials (DCT) PEAK Matrix® Assessment by the Everest Group for the third consecutive year. Science 37 is the only clinical trial site to achieve this recognition, enabling sponsors to access unreachable patients through traditional site networks. With leading telemedicine investigators, mobile nurses, and patient communities, Science 37 allows patients to participate from home, facilitating faster enrollment and reaching diverse patient populations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
none
-
News

Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary
Science 37 Holdings, Inc. (SNCE) announced the granting of inducement equity awards under the Amended and Restated 2022 Employment Inducement Incentive Award Plan. The awards were approved by the Compensation Committee for non-executive employees, including options to purchase 19,800 shares of common stock at $0.24 per share, with a 10-year term and a four-year vesting schedule.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.71%
Tags
none
News

Science 37 Holdings, Inc. Announces 1-for-20 Reverse Stock Split effective December 8, 2023

Rhea-AI Summary
Science 37 Holdings, Inc. (Nasdaq: SNCE) announced a 1-for-20 reverse stock split of its outstanding common stock to regain compliance with the $1.00 minimum bid price requirement for maintaining its listing on Nasdaq. The split will reduce the number of shares outstanding from approximately 119 million to approximately 6 million, and will be effective on December 8, 2023. The new CUSIP number for the Common Stock following the Reverse Stock Split will be 808644207.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.2%
Tags
none
-
News

Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary
Science 37 Holdings, Inc. (Nasdaq: SNCE) announced the granting of inducement equity awards under the Amended and Restated 2022 Employment Inducement Incentive Award Plan. The awards, approved by the Compensation Committee, were made to non-executive employees as a material inducement to their employment. Options to purchase 36,500 shares of Science 37 common stock at an exercise price of $0.2874 per share were granted to 2 new employees, with a 10-year term and a four-year vesting schedule.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.92%
Tags
none
-
News

Science 37 Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
Science 37 Holdings, Inc. (SNCE) reported a 50.6% increase in gross bookings, reaching $17.9 million in the third quarter of 2023. However, revenue decreased by 8.4% to $14.9 million. The company's net loss improved by 28.9% to $13.9 million, resulting in a loss per share of $0.12. Cash and Cash Equivalents as of September 30, 2023, were $56.4 million. Full year 2023 financial outlook includes updated revenue guidance of $58.0-$59.0 million and adjusted EBITDA guidance of approximately $(32.5) million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.88%
Tags
earnings
News

Science 37 to Report Third Quarter 2023 Financial Results on November 7, 2023

Rhea-AI Summary
Science 37 Holdings, Inc. (Nasdaq: SNCE) will report Q3 2023 financial results on November 7, 2023. A conference call will be held at 8:30 a.m. ET to discuss the results. The webcast can be accessed on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
conferences earnings

FAQ

What is the market cap of Science 37 Holdings (SNCE)?

The market cap of Science 37 Holdings (SNCE) is approximately 34.7M.

What does Science 37 Holdings, Inc. specialize in?

Science 37 specializes in accelerating biomedical discovery through innovative, patient-centric clinical research models using advanced telemedicine technology.

What is the Metasite™?

The Metasite™ is Science 37's proprietary virtual site platform that allows patients to participate in clinical trials from home or local healthcare providers, ensuring greater compliance and high-quality data.

What recent financial developments have occurred at Science 37?

Recent financial developments include the approval of a reverse stock split to comply with Nasdaq listing requirements and a cash tender offer by eMed to purchase all outstanding shares at $5.75 per share.

What awards has Science 37 won recently?

Science 37 recently won the “Clinical Efficiency Innovation Award” at the 8th annual MedTech Breakthrough Awards for its transformative patient recruitment solution.

How does Science 37 enhance patient recruitment for clinical trials?

Science 37 leverages AI-powered screening and centralized processes to recruit, qualify, and consent patients, significantly improving patient randomization rates and site satisfaction.

Who are Science 37's main partners?

Science 37 partners with national mobile nursing companies, pharmacy chains, patient advocacy groups, and leading technology companies to streamline the clinical trial process.

Where is Science 37 headquartered?

Science 37 is headquartered in Los Angeles, California.

What is the aim of Science 37's clinical research models?

The aim is to accelerate biomedical discovery by making clinical trials more accessible, reducing costs, and improving the efficiency of patient recruitment and data collection.

What is the significance of the reverse stock split for Science 37?

The reverse stock split is part of the company's strategy to regain compliance with Nasdaq's $1.00 minimum bid price requirement and ensure continued listing.

How can I learn more about Science 37's active studies?

You can visit the Science 37 website and navigate to the 'current studies' section to view active recruitment opportunities.

Stock SNCE logo
Science 37 Holdings, Inc.

Nasdaq:SNCE

SNCE Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

SNCE Stock Data

34.66M
5.01M
16.89%
52.18%
0.23%
Health Information Services
Healthcare
Link
United States
Research Triangle Park